12 patents
Utility
Method of Treating Gaba Mediated Disorders
23 Nov 23
Jeremy Hill, Edward Monaghan, Amy Chappell
Filed: 30 Sep 21
Utility
Methods of Treating Fibromyalgia with Neuroactive Steroids
23 Nov 23
The invention relates to methods of treating fibromyalgia in a human subject by providing the steroid of Formula (I):
Andrew D. Levin, Danielle Feldman
Filed: 30 Sep 21
Utility
Methods of Treating Female Health Conditions Related to Sex Hormones
6 Jul 23
The invention provides methods of treating female health conditions related to sex hormones by providing compositions containing the steroid CV-10155.
Andrew D. Levin, Danielle Feldman
Filed: 7 Jun 21
Utility
Compositions That Preferentially Potentiate Subtypes of Gabaa Receptors and Methods of Use Thereof
11 May 23
The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of α4β3δ GABAA receptors over α1β2γ2 GABAA receptors.
Andrew D. Levin, Neil Buckley
Filed: 30 Dec 22
Utility
Compositions that preferentially potentiate subtypes of GABA
7 Feb 23
The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of α4β3δ GABAA receptors over α1β2γ2 GABAA receptors.
Andrew D. Levin, Neil Buckley
Filed: 22 Mar 21
Utility
N-acylethanolamide derivatives and uses thereof
10 Jan 23
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.
Andrew D. Levin
Filed: 9 Dec 20
Utility
Food-independent Dosing of CV-10155 to Treat Gabaa Disorders
22 Sep 22
The invention provides methods of treating a GABAA disorder in a subject by providing an oral dose of a composition that contains CV-10155 during a dosing window in which the subject does not consume food.
Joanne Palmer-Phillips, Elizabeth Mitchell, Valerie Morisset, Amy Chappell
Filed: 18 Mar 22
Utility
Dosing of CV-10155 In the Evening or Prior to Sleep to Treat Gabaa Disorders
22 Sep 22
The invention provides methods for treating a GABAA disorders by providing a composition containing CV-10155 to a subject in the evening or prior to a period of sleep by the subject.
Joanne Palmer-Phillips, Elizabeth Mitchell, Valerie Morisset, Amy Chappell
Filed: 18 Mar 22
Utility
Compositions that preferentially potentiate subtypes of GABA
17 Aug 21
The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of α4β3δ GABAA receptors over α1β2γ2 GABAA receptors.
Andrew D. Levin, Neil Buckley
Filed: 21 Sep 20
Utility
Compositions That Preferentially Potentiate Subtypes of Gabaa Receptors and Methods of Use Thereof
8 Jul 21
The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of α4β3δ GABAA receptors over α1β2γ2 GABAA receptors.
Andrew D. Levin, Neil Buckley
Filed: 22 Mar 21
Utility
N-acylethanolamide Derivatives and Uses Thereof
1 Apr 21
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.
Andrew D. Levin
Filed: 9 Dec 20
Utility
N-acylethanolamide derivatives and uses thereof
2 Mar 21
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.
Andrew D. Levin
Filed: 12 Oct 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first